CareDx says study links early AlloSure elevation after kidney transplant to higher 3-year graft loss risk

CareDx, Inc.

CareDx, Inc.

CDNA

0.00
  • CareDx flagged new real-world and prospective transplant studies to be presented at the American Transplant Congress 2026 on June 20-24.
  • Kidney data tied early, sustained AlloSure elevations to worse long-term graft outcomes, while transient rises that normalized tracked with more stable courses.
  • A prospective antibody-mediated rejection study showed AlloSure stayed elevated despite improvement in other clinical indicators, signaling ongoing graft injury.
  • A large multicenter analysis linked elevated AlloSure to active alloimmune injury patterns, including cases not captured by standard antibody-based classifications.
  • Heart findings connected higher AlloMap scores to later AlloSure Heart increases, supporting earlier detection of immune activation for surveillance strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.